Insider Buying Emerges: Social media chatter highlights a recent director purchase of Insulet shares, underscoring confidence in the company's recurring revenue model tied to its Omnipod insulin delivery system amid growing diabetes market demand.
Analyst Target Adjustments: Discussions note Truist's decision to lower price targets, sparking debate on how such moves reflect broader sector pressures even as participants praise the firm's execution in medical devices.
Sector Comparisons Surface: Observers frequently pair PODD with peers in diabetes technology, emphasizing its competitive positioning while acknowledging mixed technical signals in recent market evaluations.
Note: This discussion summary was generated from an AI condensation of post data.
Insulet Corporation Insider Trading Activity
Insulet Corporation insiders have traded $PODD stock on the open market 5 times in the past 6 months. Of those trades, 4 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $PODD stock by insiders over the last 6 months:
- ASHLEY MCEVOY (President and CEO) purchased 4,300 shares for an estimated $1,029,205
- MICHAEL R MINOGUE purchased 2,030 shares for an estimated $499,846
- ELIZABETH H WEATHERMAN purchased 3,450 shares for an estimated $497,489
- TIMOTHY C. STONESIFER purchased 2,790 shares for an estimated $400,392
- LUCIANA BORIO sold 418 shares for an estimated $59,886
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Insulet Corporation Revenue
Insulet Corporation had revenues of $761.7M in Q1 2026. This is an increase of 81.14% from the same period in the prior year.
You can track PODD financials on Quiver Quantitative's PODD stock page.
You can access data on PODD stock through the Quiver Quantitative API.
Insulet Corporation Congressional Stock Trading
Members of Congress have traded $PODD stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PODD stock by members of Congress over the last 6 months:
- SENATOR TINA SMITH has traded it 2 times. They made 0 purchases and 2 sales worth up to $500,000 on 05/07, 04/29.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Insulet Corporation Hedge Fund Activity
We have seen 405 institutional investors add shares of Insulet Corporation stock to their portfolio, and 453 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS removed 2,739,416 shares (-62.1%) from their portfolio in Q1 2026, for an estimated $574,839,053
- FMR LLC removed 2,350,642 shares (-37.2%) from their portfolio in Q1 2026, for an estimated $493,258,717
- AQR CAPITAL MANAGEMENT LLC added 1,139,609 shares (+248.2%) to their portfolio in Q1 2026, for an estimated $239,135,552
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 1,011,369 shares (+462.7%) to their portfolio in Q1 2026, for an estimated $212,225,670
- JUPITER ASSET MANAGEMENT LTD added 475,438 shares (+202.8%) to their portfolio in Q1 2026, for an estimated $99,765,909
- SOLEUS CAPITAL MANAGEMENT, L.P. added 412,500 shares (+275.0%) to their portfolio in Q1 2026, for an estimated $86,559,000
- TWO SIGMA INVESTMENTS, LP added 395,627 shares (+107.9%) to their portfolio in Q1 2026, for an estimated $83,018,369
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Insulet Corporation Analyst Ratings
Wall Street analysts have issued reports on $PODD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 05/20/2026
- JP Morgan issued a "Overweight" rating on 05/07/2026
- Barclays issued a "Underweight" rating on 01/12/2026
To track analyst ratings and price targets for Insulet Corporation, check out Quiver Quantitative's $PODD forecast page.
Insulet Corporation Price Targets
Multiple analysts have issued price targets for $PODD recently. We have seen 16 analysts offer price targets for $PODD in the last 6 months, with a median target of $227.5.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $219.0 on 06/12/2026
- Joanne Wuensch from Citigroup set a target price of $165.0 on 05/28/2026
- Marie Thibault from BTIG set a target price of $235.0 on 05/27/2026
- Shagun Singh from RBC Capital set a target price of $280.0 on 05/27/2026
- Travis Steed from B of A Securities set a target price of $208.0 on 05/18/2026
- Matt Miksic from Barclays set a target price of $198.0 on 05/08/2026
- Lee Hambright from Bernstein set a target price of $200.0 on 05/07/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
